CoChat

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer

Kluth, Martina, Harasimowicz, Silvia, Burkhardt, Lia, Grupp, Katharina, Krohn, Antje, Prien, Kristina, Gjoni, Jovisa, Haß, Thomas, Galal, Rami, Graefen, Markus, Haese, Alexander, Simon, Ronald, Hühne‐Simon, Julia, Koop, Christina, Korbel, Jan, Weischenfeld, Joachim, Huland, Hartwig, Sauter, Guido, Quaas, Alexander, Wilczak, Waldemar, Tsourlakis, Maria‐Christina, Minner, Sarah, Schlomm, Thorsten · 2014 · International Journal of Cancer
Cited by 104

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Despite a multitude of p53 immunohistochemistry (IHC) studies, data on the combined effect of nuclear p53 protein accumulation and TP53 genomic inactivation are lacking for prostate cancer. A tissue microarray including 11,152 prostate cancer samples was analyzed by p53 IHC and fluorescence in situ hybridization. Nuclear p53 accumulation was found in 10.1% of patients including 1.4% with high‐level and 8.7% with low‐level immunostaining. TP53 sequencing revealed that 17 of 22 (77%) cases with high‐level p53 immunostaining, but only 3% (1 of 31) low‐level p53 cases carried putative dominant‐negative mutations. TP53 deletions occurred in 14.8% of cancers. Both deletions and protein accumulation were linked to unfavorable tumor phenotype and prostate specific antigen (PSA) recurrence ( p < 0.0001 each). The combination of both methods revealed subgroups with remarkable differences in their clinical course. Tumors with either TP53 deletion (14%) or low‐level p53 positivity (8.7%) had identical risks of PSA recurrence, which were markedly higher than in cancers without p53 alterations ( p < 0.0001). Tumors with both p53 deletion and low‐level p53 positivity (1.5%) had a worse prognosis than patients with only one of these alterations ( p < 0.0001). Tumors with strong p53 immunostaining or homozygous inactivation through deletion of one allele and disrupting translocation involving the second allele had the worst outcome, independent from clinical and pathological parameters. These data demonstrate a differential clinical impact of various TP53 alterations in prostate cancer. Strong p53 immunostaining—most likely accompanying dominant negative or oncogenic p53 mutation—has independent prognostic relevance and may thus represent a clinical useful molecular feature of prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.28784

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Kluth, M., Harasimowicz, S., Burkhardt, L., Grupp, K., Krohn, A., Prien, K., Gjoni, J., Haß, T., Galal, R., Graefen, M., Haese, A., Simon, R., Hühne‐Simon, J., Koop, C., Korbel, J., Weischenfeld, J., Huland, H., Sauter, G., Quaas, A., Wilczak, W., Tsourlakis, M., Minner, S., & Schlomm, T.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2014-04-26
Volume
135
Issue
6
Pages
1369-1380
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W1814937376
Cited by
104
References
3
FWCI
8.48
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.